Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers, yet it stands out as one of the most aggressive subtypes—marked by high histological grade, early metastasis, and a lack of targeted therapies like hormone or HER2 inhibitors. For patients undergoing neoadjuvant chemotherapy (NAC)—a standard treatment to shrink tumors before surgery—achieving a pathological complete response (pCR, no residual invasive cancer) is strongly linked to better long-term survival. But for those who don’t reach pCR, predicting outcomes remains tricky. How can doctors identify which non-pCR patients are at highest risk—and who might benefit from additional treatments? A 2020 study from researchers at Peking University First Hospital suggests the answer lies in the tumor’s immune microenvironment: specifically, the types of tumor-infiltrating lymphocytes (TILs) left in residual tumors after NAC.
What Are TILs, and Why Do They Matter?
TILs are immune cells that infiltrate the tumor microenvironment, playing a key role in the body’s anti-tumor response. Previous research has shown that higher TIL levels correlate with better responses to NAC and longer survival in TNBC. But most studies have looked at total TILs, not specific subtypes. This study focused on four TIL types:
- CD4+ T cells: Helper T cells that activate other immune cells (like CD8+ T cells) to fight cancer.
- CD8+ T cells: Cytotoxic “killer” T cells that directly destroy tumor cells.
- CD20+ B cells: Lymphocytes that drive humoral immunity (antibody production)—their role in breast cancer is less clear, with some evidence linking them to pro-tumor inflammation.
- CD68+ macrophages: Immune cells that can either promote (M2 type) or inhibit (M1 type) tumor growth; CD68 is a marker for total tumor-associated macrophages (TAMs).
The Study Design
The researchers analyzed data from 37 TNBC patients treated at Peking University First Hospital between 2008 and 2014. All received six cycles of NAC (taxane + anthracycline) but did not achieve pCR (defined as no residual invasive cancer in the breast or lymph nodes). Using immunohistochemistry, they counted TILs in residual tumor tissue and split patients into “high” or “low” groups based on the median density of each subtype. They then used statistical tests (Fisher’s exact test for clinicopathological correlations, Kaplan-Meier curves for survival) to see how TIL subtypes related to outcomes.
Key Findings
Over a median follow-up of 50 months (range: 17–106 months), the team found:
- High CD4+ TILs = Better Survival: Patients with more CD4+ helper T cells had significantly longer disease-free survival (DFS, time to first recurrence/metastasis) and overall survival (OS, time to death). The 5-year DFS rate was higher in the high CD4+ group (P=0.005), and 5-year OS was also improved (P=0.021).
- High CD8+ TILs = Better DFS: More CD8+ killer T cells correlated with longer time without recurrence (P=0.018).
- Low CD20+ TILs = Better OS: Fewer CD20+ B cells were linked to longer overall survival (P=0.042).
- Ratio Matters Most: Patients with a CD4+/CD20+ ratio >1 or CD8+/CD20+ ratio >1 had the best outcomes. For example, those with a CD4+/CD20+ ratio above 1 had a statistically significant improvement in DFS (P=0.001) and OS (P=0.002).
Notably, TIL subtypes didn’t correlate with clinicopathological features (like age, tumor stage, or NAC response), meaning they could act as independent prognostic markers—a critical factor for personalized care.
What Do These Results Mean?
The findings build on growing evidence that the immune microenvironment is a powerful predictor of TNBC outcomes. Here’s why each subtype matters:
- CD4+ T cells: Even though they don’t directly kill tumor cells, they’re essential for activating other anti-tumor immune cells. Their presence in residual tumors suggests an ongoing anti-tumor response, which improves survival.
- CD8+ T cells: These “killer” cells are the frontline of tumor immunity. Higher levels mean more cells are actively attacking residual cancer.
- CD20+ B cells: The study’s link between low CD20+ TILs and better survival aligns with emerging research that B cells can promote tumor growth by creating a pro-inflammatory, immunosuppressive environment. A higher ratio of anti-tumor T cells (CD4+/CD8+) to pro-tumor B cells (CD20+) likely tips the balance in favor of the immune system.
CD68+ macrophages didn’t show a clear trend in this study—possibly due to the small sample size or the fact that CD68 marks all macrophages (both pro- and anti-tumor types). Future research focusing on macrophage polarization (M1 vs. M2) might yield more insights.
Limitations and Next Steps
The study’s biggest limitation is its small sample size (37 patients), which limits the power to detect weaker correlations (like CD68+ TILs and survival). However, the statistically significant findings for CD4+, CD8+, and CD20+ TILs—along with the ratio analysis—suggest these markers are worth exploring in larger, multi-center studies. The team also noted that all patients received the same NAC regimen (taxane + anthracycline), so results may not apply to other chemotherapy combinations.
Why This Matters for Patients
For TNBC patients who don’t achieve pCR after NAC, the current standard is often additional adjuvant therapy (like capecitabine, as shown in the CREATE-X trial). But not all non-pCR patients need intense treatment—some have better outcomes than others. This study suggests TIL subtypes could help doctors stratify risk: patients with high CD4+/CD8+ TILs or favorable ratios might not need aggressive follow-up, while those with low anti-tumor TILs or high CD20+ TILs could benefit from earlier interventions.
Conclusion
The immune microenvironment of residual tumors holds critical clues for TNBC patients after NAC. High CD4+ or CD8+ TILs, low CD20+ TILs, or a favorable ratio of anti-tumor to pro-tumor TILs are all linked to better survival. While more research is needed to validate these findings, this study adds to a growing body of work showing that TIL subtypes are not just “background noise”—they’re actionable biomarkers that could transform how we care for TNBC patients.
The study was conducted by Yu-Ge Bai, Guo-Xuan Gao, Hong Zhang, Shuang Zhang, Yin-Hua Liu, Xue-Ning Duan, and Ling Xu from the Breast Disease Center at Peking University First Hospital and Beijing Friendship Hospital. It was published in the Chinese Medical Journal in 2020.
doi.org/10.1097/CM9.0000000000000656
Was this helpful?
0 / 0